CSL Ltd - Company Profile
Powered by 
All the sales intelligence you need on CSL Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how CSL Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with CSL Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CSL Ltd (CSL) is a biotechnology company. It discovers, develops, manufactures, commercializes and distributes biopharmaceuticals. The company's product portfolio comprises treatments for hemophilia and immune deficiency, vaccines to prevent influenza and therapies for iron deficiency and kidney conditions. CSL's proprietary platform consists of plasma and recombinant protein technology, cell and gene therapy and adjuvant cell-based egg-based mRNA. CSL focuses on conditions related to hematology, respiratory, cardiovascular, metabolic, nephrology and transplant, immunology and vaccines, among others. The company operates in various countries, including Australia, China, Germany, Switzerland, the US, Hungary, Puerto Rico, the UK, Italy, Japan, the Netherlands, and Spain. CSL is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
655 Elizabeth Street, Melbourne, Victoria, 3000
Website
www.csl.com
Telephone
61 39 3891911
No of Employees
32,065
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CSL (ASX)
Revenue (2024)
$15.6B
5.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
13.6%
(2024 vs 2023)
Market Cap*
$40.2B
Net Profit Margin (2024)
XYZ
8.1%
(2024 vs 2023)
* As of and is in US$
CSL Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapy Areas: | Ferinject |
| Immunology | Injectafer |
| Hematology | Venofer |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, CSL Seqirus entered into a new multi-year pandemic preparedness agreement with PAHO’s Regional Revolving Fund to strengthen influenza pandemic preparedness across Latin America and the Caribbean. |
| 2026 | Corporate Changes/Expansions | In March, the company expanded its manufacturing facility in Kankakee, Illinois, the US. |
| 2026 | Contracts/Agreements | In March, CSL Seqirus secured a new contract to help the Public Health Agency of Canada's (PHAC) influenza pandemic preparedness plans. |
Competitor Comparison
| Key Parameters | CSL Ltd | AbbVie Inc | AstraZeneca Plc | Bayer AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | United Kingdom | Germany | United States of America |
| City | Melbourne | North Chicago | Cambridge | Leverkusen | Princeton |
| State/Province | Victoria | Illinois | Cambridgeshire | Nordrhein-Westfalen | New Jersey |
| No. of Employees | 32,065 | 57,000 | 96,100 | 87,757 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Brian McNamee | Chairman | Executive Board | 2018 | 69 |
| Gordon Naylor | Chief Executive Officer; Director; Managing Director | Executive Board | 2026 | - |
| Ken Lim | Chief Financial Officer | Senior Management | 2025 | 52 |
| Mary Oates | Chief Operating Officer | Senior Management | 2025 | 63 |
| Bill Mezzanotte, M.D. | Chief Medical Officer; Executive Vice President; Head - Research and Development | Senior Management | 2018 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer